Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
As of today, Gilead Sciences(GILD) shares are valued at $139.07. The company's market cap stands at 171.43B, with a P/E ratio of 20.25 and a dividend yield of 2.3%.
On 2026-03-24, Gilead Sciences(GILD) stock traded between a low of $136.47 and a high of $139.65. Shares are currently priced at $139.07, which is +1.9% above the low and -0.4% below the high.
The Gilead Sciences(GILD)'s current trading volume is 6.73M, compared to an average daily volume of 6.85M.
In the last year, Gilead Sciences(GILD) shares hit a 52-week high of $157.29 and a 52-week low of $93.37.
In the last year, Gilead Sciences(GILD) shares hit a 52-week high of $157.29 and a 52-week low of $93.37.
GILD News
Gilead on Monday agreed to acquire Ouro Medicines for $1.675 billion in upfront cash, with additional contingent milestone payments of up to $500 million. Stra...
Gilead Sciences (NasdaqGS:GILD) has agreed to acquire Ouro Medicines, adding an FDA fast-tracked, orphan-designated T cell engager for autoimmune diseases to it...
Galapagos (GLPG) announced that, following Gilead’s (GILD) entering into an agreement to acquire Ouro Medicines, Galapagos and Gilead are in advanced partnershi...
Analyst ratings
75%
of 32 ratingsMore GILD News
Markets These Stocks Are Today’s Movers: Tesla, Jefferies, Apollo, Gilead, Estée Lauder, and More In this article TSLA JEF APO GILD EL Traders working at the Ne...
(RTTNews) - Gilead Sciences Inc. (GILD), on Monday, entered into a definitive agreement to acquire privately held Ouro Medicines. The deal includes $1.675 bill...
Gilead Sciences (GILD) has agreed to acquire privately held biotech firm Ouro Medicines in a deal valued at over $2 billion to expand into immunology. The trans...
Gilead Sciences plans to acquire Ouro Medicines for up to about $2.18 billion. Stephen Lam/Reuters Gilead Sciences GILD 0.09 %increase; green up pointing trian...
Gilead (GILD) Sciences is at an advanced stage in talks to acquire autoimmune disease-focused biotech Ouro Medicines for up to $2B, people familiar with the mat...
Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Gilead Sciences and keeping the price target at $162.00. Tazeen Ahmad has given...
Gilead Sciences (GILD) announced an update on their ongoing clinical study. The Phase 2 study titled “A Phase 2, Single-Arm Study of Obeldesivir for Postexposu...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.